Hydrocodone: Rescheduled, Repositioned & Reinvented
Pain Insights, Inc. releases a comprehensive market research study assessing two major intertwined events in the pain market: the rescheduling of hydrocodone combinations and the pending introduction of abuse-deterrent, extended-release, single-entity hydrocodone products.
FAIRFIELD, N.J., Dec. 4, 2014 /PRNewswire/ -- The introduction of abuse-deterrent, extended-release hydrocodone products and the rescheduling of hydrocodone combination products (HCPs) will have a significant impact on the pain market, according to a new primary market research study by Pain Insights, Inc.
Logo - http://photos.prnewswire.com/prnh/20141203/162305LOGO
Background:
On November 20, 2014, the U.S. FDA approved Hysingla ER (extended-release hydrocodone bitartrate) for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. In addition, the approved labeling for Hysingla ER describes the product's abuse-deterrent properties.
Effective October 6, 2014, the scheduling change for hydrocodone combination products from Schedule III to Schedule II status took effect. Hydrocodone-acetaminophen products are the most frequently prescribed opioids in the U.S. with over 129 million prescriptions dispensed in 2013 (IMSHealth™).
Study Details:
The comprehensive market research study was conducted among primary care physicians and other key specialties prescribing hydrocodone combination products. The report assesses the market changing events of the anticipated adoption of an abuse-deterrent, extended-release hydrocodone product, based on a detailed product profile, and how more stringent Schedule II regulations will impact prescribing of hydrocodone combination products.
Sample findings:
The majority of practitioners (85%) expressed an interest in prescribing an abuse-deterrent, extended-release hydrocodone product and found it at least somewhat differentiated from currently available extended-release opioids for chronic pain.
Practitioners reported that rescheduling will alter their prescribing of HCPs by significant percentages for the treatment of acute/chronic pain and have a resultant effect on the use of alternative medications.
Agents from several analgesic segments will garner increased prescribing due to the rescheduling of hydrocodone combinations.
Rescheduling of hydrocodone combinations will increase the value proposition for abuse-deterrent, extended-release hydrocodone products.
Practitioners less inclined to prescribe hydrocodone combinations after rescheduling value the abuse deterrent features of an extended-release hydrocodone product greater than those not anticipating any impact on their prescribing of hydrocodone combinations.
The study will lend guidance for new product development strategies, educational programs, strategic planning and forecasting, regulatory guidance, and supply chain optimization.
Key questions answered in this report:
How much will prescribing of hydrocodone combination products change for acute/chronic pain as a result of rescheduling?
What will be the share impact for specific alternative medications (opioids/non-opioids) for acute/chronic pain?
What is the size of the market opportunity for an abuse-deterrent, extended-release formulation of hydrocodone? What products will be displaced? What benefits comprise the value proposition?
What will be the impact of other new products, including Xartemis™ XR, Zohydro™ ER, and Evzio™.
About Pain Insights, Inc.
Pain Insights, Inc. is a full service marketing research and strategic planning firm established in 2001, exclusively focused on the area of pain management. The principals each have more than 25 years of experience in this area.
Company and brand names mentioned are trademarks of their respective owners.
For more information, please contact:
William Kolek
973-808-1147
-or-
Robert Catuosco
973-808-1116
Email
Website: www.paininsights.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hydrocodone-rescheduled-repositioned--reinvented-300004675.html
SOURCE Pain Insights, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article